Genomic epidemiology of the UK outbreak of the emerging human fungal pathogen Candida auris by Rhodes, J et al.
Rhodes et al. Emerging Microbes & Infections  (2018) 7:43 
DOI 10.1038/s41426-018-0045-x Emerging Microbes & Infections
ART ICLE Open Ac ce s s
Genomic epidemiology of the UK outbreak
of the emerging human fungal pathogen
Candida auris
Johanna Rhodes1, Alireza Abdolrasouli2,3, Rhys A. Farrer1, Christina A. Cuomo4, David M. Aanensen1,5,
Darius Armstrong-James2, Matthew C. Fisher1 and Silke Schelenz2
Abstract
Candida auris was first described in 2009, and it has since caused nosocomial outbreaks, invasive infections, and
fungaemia across at least 19 countries on five continents. An outbreak of C. auris occurred in a specialized
cardiothoracic London hospital between April 2015 and November 2016, which to date has been the largest outbreak
in the UK, involving a total of 72 patients. To understand the genetic epidemiology of C. auris infection both within this
hospital and within a global context, we sequenced the outbreak isolate genomes using Oxford Nanopore
Technologies and Illumina platforms to detect antifungal resistance alleles and reannotate the C. auris genome.
Phylogenomic analysis placed the UK outbreak in the India/Pakistan clade, demonstrating an Asian origin; the
outbreak showed similar genetic diversity to that of the entire clade, and limited local spatiotemporal clustering was
observed. One isolate displayed resistance to both echinocandins and 5-flucytosine; the former was associated with a
serine to tyrosine amino acid substitution in the gene FKS1, and the latter was associated with a phenylalanine to
isoleucine substitution in the gene FUR1. These mutations add to a growing body of research on multiple antifungal
drug targets in this organism. Multiple differential episodic selection of antifungal resistant genotypes has occurred
within a genetically heterogenous population across this outbreak, creating a resilient pathogen and making it difficult
to define local-scale patterns of transmission and implement outbreak control measures.
Introduction
The emerging fungal pathogen Candida auris causes
nosocomial invasive infections, predominantly in inten-
sive care units (ICU). C. auris has a multidrug resistant
(MDR) phenotype1, 2 with varying susceptibility to other
azole drugs, amphotericin B and echinocandins3–6 and
acquired resistance to fluconazole7.
Since its first description in 2009 in Japan8, C. auris
infections have been reported in several countries1, 4, 6, 9–
16 with identification routinely carried out by matrix-
assisted laser desorption ionization time of flight mass
spectrometry (MALDI-TOF MS)11, 14, 15. However, this
method of identification can misidentify C. auris as other
Candida species if commercial yeast identification data-
bases are used17. Clonality has previously been identified
within C. auris isolates from India, Brazil, South Africa,
and South Korea using amplified fragment length poly-
morphism (AFLP) and multilocus sequence typing
(MLST)9, 14, 18. However, given the low discriminatory
power and reproducibility of these techniques, genetic
relatedness between isolates cannot be investigated14;
while not currently routine in the investigation of fungal
outbreaks, whole-genome sequencing (WGS) provides
increased power to assess the relatedness of isolates to
analyze patterns of nosocomial infections and global
spread19.
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In 2016, we described the first large-scale C. auris
outbreak (April 2015–November 2016) occurring within a
single specialist cardiothoracic hospital in London11.
Owing to the high uncertainty of the time and source of
introduction of C. auris into the hospital, the rapid
development of a molecular epidemiological toolkit was
required. Outbreaks of other fungal pathogens have been
previously investigated using short-read WGS, which
provided sufficient information to discriminate between
isolates and their phylogenetic relationships using single
nucleotide polymorphism (SNP) analysis20–22. Recently,
the handheld, portable MinION sequencer, manufactured
by Oxford Nanopore Technologies, UK (ONT), has made
rapid WGS widely available in the field and has been
successfully used to analyze the molecular epidemiology
of recent Ebola and Zika viruses outbreaks23, 24.
Here, we describe the use of MinION nanopore
sequencing technology on a pathogenic fungus to deter-
mine the genetic epidemiology of this fungal outbreak,
both within the UK hospital and within a global context,
alongside a reannotation of the genome of C. auris and
definition of novel antifungal resistance alleles.
Results
We sequenced 25 clinical C. auris isolates from a
recently described outbreak11, which included eight iso-
lates derived from four patients taken several days apart to
establish possible within-patient diversity. In addition, we
also sequenced two samples from the hospital environ-
ment to better represent the overall genetic diversity
within the impacted hospital.
Rapid generation of outbreak C. auris reference genomes
We assembled five high-quality hybrid de novo refer-
ence genomes for C. auris using Illumina short-read
sequences and MinION long-read sequences generated
over 48 h. Five isolates were chosen to cover a range of
dates (October 2015 to March 2016). Isolate 16B25 had
the best overall assembly quality of 110 contigs, N50
= 396,317 bp and a total sequence length of 12.3Mb
(Table 1; Supplementary Table S1). Approximately
98.94% of the 16B25 assembly mapped to the Pakistani C.
auris genome B8441 assembled by Lockhart et al.1 Fur-
ther analysis revealed that the unmapped 1.06% of the
16B25 assembly was distributed throughout the genome
and was likely attributed to genetic variation between the
two isolates.
We generated an average of 5.2 million Illumina reads
passing quality control for 27 isolates recovered during
the outbreak that mapped closely (average 95.5%) to our
reference genome (Supplemental Material Table S2). A
total of 5366 protein coding genes, 4 rRNAs, and 156
tRNAs were predicted using the genome annotation
pipeline described in Supplementary Methods. Table 2
summarizes the general features of 16B25, along with
those of other pathogenic Candida genomes. The number
of protein coding genes presented here is in line with the
predicted number of genes in C. lusitaniae25 (n= 5941),
the closest known relative of C. auris.
There are fewer protein coding genes, tRNAs and
rRNAs predicted in this genome than previously reported
for C. auris Ci 6684 in Chatterjee et al.26, as shown in
Table 1. Running our annotation pipeline on the B8441
isolate presented in Lockhart et al.1 found similar num-
bers of protein coding genes, rRNAs, and tRNAs
(Table 1). Therefore, the different total numbers between
16B25 and Ci 6684 are likely due to different annotation
pipelines and not the quality of the reference assemblies.
The number of protein coding genes identified in Chat-
terjee et al. (n= 8358) was substantially greater than that
found in other Candida species (Table 1) and is likely
inflated due to over-prediction of short sequences, lack of
filtering of repetitive sequences, and the use of only
GenemarkS to predict the start of genes; our pipeline used
Table 1 Summary of assembly and annotation statistics of the C. auris 16B25 genome, the C. auris B8441 reference1, the
C. auris Ci 6684 reference26, and other pathogenic Candida species reference genomes25
Species Genome size
(Mb)











12.3 110 45.13 5366 1564 Haploid
C. auris (B8441) 12.4 19 45.13 5439 1548 Haploid
C. auris (Ci 6684) 12.5 99 44.53 8358 1025 Haploid
C. albicans SC5314 14.3 7 33.5 6107 1468 Diploid
C. tropicalis MYA-3404 14.5 24 33.1 6163 1454 Diploid
C. parapsilosis 13.1 24 38.7 5733 1533 Diploid
C. lusitaniae 12.1 9 44.5 5941 1382 Haploid
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additional criteria to achieve a predicted set of high-
confidence genes.
Phylogenetic analysis reveals an Indian/Pakistani origin of
C. auris outbreak
Phylogenetic analysis based on whole-genome SNPs
revealed that the UK outbreak had an Indian/Pakistani
origin (Fig. 1). SNP calls for isolates from Venezuela,
India, Pakistan, Japan, and South Africa1, 27 were also
included to add geographic context to the outbreak. The
UK outbreak isolates were in the same clade as those from
India and Pakistan (Fig. 1a); on average, 240 SNPs sepa-
rated UK outbreak isolates from isolates collected in India
and Pakistan. There were no known patient travel links to
India or Pakistan prior to admission into the hospital,
however. We found an average of 103 SNPs separating
isolates within the UK outbreak; later isolates in Clade A
towards the end of the outbreak (Fig. 1b) exhibited 134
SNPs separating them compared to earlier isolates in
Clades B and C isolated at the start of the outbreak
(Fig. 1b), which showed an average of 90 SNPs separating
them.
Table 2 MICs at time of isolation of all isolates included in this study and associated molecular resistance mechanism
identified in this study
Isolate ID ANI MICA CAS 5FC POS VOR ITR FLU AmpB Molecular resistance mechanism
15B5 0.12 0.12 0.25 0.12 8 8 16 256 2 Y132F in ERG11
15B6 0.06 0.06 0.06 0.06 0.015 0.25 0.06 256 1 Y132F in ERG11
15B10 0.12 0.12 0.5 0.12 8 8 16 256 2 Y132F in ERG11
16B12 0.12 0.12 0.5 0.25 8 8 16 256 2 Y132F in ERG11
16B13 0.12 0.12 0.25 0.06 0.03 0.5 0.06 256 1 Y132F in ERG11
16I29b N/A N/A N/A N/A N/A N/A N/A N/A N/A Y132F in ERG11
16I29a N/A N/A N/A N/A N/A N/A N/A N/A N/A Y132F in ERG11
16B18 0.25 0.25 1 0.06 0.12 2 0.12 256 1 Y132F in ERG11
16B15a 0.12 0.06 0.12 0.06 0.008 0.06 0.015 16 0.5 Y132F in ERG11
16I17 N/A N/A N/A N/A N/A N/A N/A N/A N/A Y132F in ERG11
16B20 0.06 0.12 0.5 0.06 8 8 16 256 1 Y132F in ERG11
16B16 0.12 0.12 0.25 0.06 0.03 0.25 0.03 256 1 Y132F in ERG11
16B21 0.12 0.12 0.25 0.06 0.12 0.5 0.03 16 1 Y132F in ERG11
16B22a 0.12 0.12 0.25 0.06 0.008 0.25 0.03 128 0.5 Y132F in ERG11
16B24a 0.12 0.12 0.5 0.06 8 8 8 256 2 Y132F in ERG11
16B22b 0.12 0.12 0.25 0.06 4 8 2 256 1 Y132F in ERG11
16B24b 0.12 0.12 0.25 0.06 8 8 2 256 1 Y132F in ERG11
16B25 0.12 0.12 0.25 0.06 0.03 0.12 0.03 64 1 Y132F in ERG11
16I27a N/A N/A N/A N/A N/A N/A N/A N/A N/A Y132F in ERG11
16B26 0.12 0.12 0.25 0.06 8 8 16 256 1 Y132F in ERG11
16B27b 0.12 0.12 1 0.12 8 8 16 256 0.5 Y132F in ERG11
16I30 0.25 0.12 0.5 0.12 8 8 16 256 2 Y132F in ERG11
16B15b 8 8 8 64 0.015 0.25 0.03 8 1 S652Y in FKS1; F211I in FUR1; Y132F in ERG11
16B30 0.12 0.06 0.12 0.06 0.15 0.5 0.06 128 1 Y132F in ERG11
16B31 0.12 0.06 0.12 0.06 0.03 0.5 0.06 256 1 Y132F in ERG11
16I33 0.06 0.06 0.06 0.06 0.06 0.06 0.03 128 0.5 Y132F in ERG11
16I34 0.06 0.06 0.06 0.06 0.008 0.25 0.03 256 0.5 Y132F in ERG11
MICs for FLU, ITR, VOR, POS, CAS, MICA AmpB, and ANI were above these tentative epidemiological cutoffs (ECOFF)3 and C. albicans ECOFF for 5FC27, 60 and are
therefore resistant (in bold font)
ANI anidulafungin, MICA micafungin, CAScaspofungin, 5FC 5-fluorocytosine, POS posaconazole, VOR voriconazole, ITR itraconazole, FLU fluconazole, AmpB
amphotericin B, N/A no MICs carried out
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Fig. 1 (See legend on next page.)
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Fitting root-to-tip regression showed there was a linear
relationship between sampling time (measured in days)
and the expected number of nucleotide substitutions
along the tree, demonstrating clock-like evolution across
the timescale of the outbreak (Fig. 2). There was a strong
association between genetic distances and sampling dates
(R2= 0.9992), showing that the data set has a reasonable
temporal signal for further molecular clock analysis. The
evolutionary rate of nuclear DNA (calculated from the
slope of the regression) equated to 1.002e−3 substitutions
per generation, which is comparable to nuclear DNA of
other fungal species, such as Schizosaccharomyces pombe
beer strains (3.0e−328) and Saccharomyces cerevisiae (5.7e
−329). The time to the most recent common ancestor
(TMRCA) was estimated to be late January 2015, two
months prior to the first patient identified with a C. auris
infection. One isolate, 16B15b, showed less genetic
divergence from the root than expected given its date of
sampling, which was perhaps an indication of excessive
passage or recombination.
Clinical isolates of C. auris show multidrug resistance
Out of the 27C. auris outbreak isolates, six displayed
reduced susceptibility to two or more classes of antifungal
drugs, and thirteen isolates displayed reduced suscept-
ibility to two or more azole antifungal drugs (Table 2).
Only six isolates displayed reduced susceptibility to only
one drug, fluconazole (Minimum Inhibitory Concentra-
tion (MIC): ≥256 µg/ml). Most (n= 24) isolates expressed
elevated MICs to fluconazole (MIC: ≥256 µg/ml) with
varying MICs to itraconazole (MIC: 0.03 µg/ml to ≥16 µg/
ml), voriconazole (MIC: 0.12 µg/ml to 8 µg/ml) and
posaconazole. Five isolates also displayed reduced sus-
ceptibility to amphotericin B (MIC: ≥2 µg/ml). Although
resistance to amphotericin B is uncommon in Candida
species30, studies have associated mutations in the ERG2,
ERG3, ERG5, ERG6, and ERG11 genes with the depletion
of ergosterol and amphotericin B resistance30, 31. We did
not identify any mutations in the aforementioned ERG
genes in isolates displaying reduced susceptibility.
Expanding the search across the genome found no can-
didate SNPs that were unique to isolates displaying
reduced susceptibility.
One isolate (16B15b) displayed elevated MICs to all
echinocandin drugs (MIC: ≥8 µg/ml) but remained sus-
ceptible to all azole drugs, with the exception to fluco-
nazole. 16B15b also displayed reduced susceptibility to
flucytosine (MIC: ≥64 µg/ml), which was not seen in the
other isolates; therefore, resistance and any associated
mutations were unique to this outbreak isolate. This
isolate belonged to a patient who received anidulafungin
for 7 days for pancolitis, developing C. auris candidemia
11 days afterwards, at which point isolate 16B15a was
recovered. Treatment was switched to amphotericin and
5-flucytosine for 2 weeks. 6 days after completing this
treatment, pan-resistant C. auris (16B15b) was recovered
from the vascular tip. Previous studies in Aspergillus and
Candida species identified mutations in FKS1 associated
with reduced echinocandin susceptibility or resistance32,
33; one non-synonymous SNP (nsSNP) causing a serine to
tyrosine substitution (S652Y) was identified in the C. auris
FKS1 gene from the 16B25 reannotated genome. Our
updated annotation protocol comparing multiple lines of
evidence predicted an extended first exon for FKS1 in
comparison to the sequence submitted to GenBank
Fig. 1 Phylogenetic analysis of C. auris isolates with bootstrap support (500 replicates) performed on WGS SNP data to generate
maximum-likelihood phylogenies. Branches were supported 75% or higher unless otherwise stated. Branch lengths represent the average
expected rate of substitutions per site. a Outbreak isolates from the UK (shown in blue) were combined with isolates from around the globe,
including India (orange), Pakistan (red), Venezuela (pink), Japan (turquoise), and South Africa (green), to infer a possible geographical origin. Isolates
with known mutations in the ERG11 gene associated with resistance to fluconazole in C. albicans are shaded: Y132F in red, K143R in yellow, and F126L
in blue. b Given the likely Indian/Pakistani origin of the outbreak isolates, phylogenetic analysis was repeated (as stated above), excluding isolates
from South Africa, Venezuela, and Japan, to illustrate the UK outbreak. Isolates separating either into Cluster A (green), B (purple), or C (pink) are
depicted to reflect likely introductions into the hospital
Fig. 2 Root-to-tip regression analysis of all 27 C. auris outbreak
isolates. Genetic distance is plotted against sampling time for the
phylogeny of the C. auris outbreak. Each data point represents a tip on
the phylogeny. The R2 for the regression and the slope, reflecting the
evolutionary rate (in substitutions per site per day) is also shown
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(PIS58465); a comparison of the two protein sequences
indicated that position 652 in the reannotated FKS1
sequence is analogous to position 639 in the GenBank
entry, resulting in S639Y in FKS1 hotspot 1 (HS1).
Another nsSNP caused a phenylalanine to isoleucine
substitution (F211I) in the FUR1 gene identified in the
16B25 reannotated genome, which has a role in 5-
flucytosine resistance34. Although neither of these muta-
tions has been previously reported, single nucleotide
changes in FUR1 in C. albicans and C. lusitaniae have
been associated with 5-flucytosine resistance34, 35.
Orthologous sequences to C. albicans ERG11 were
screened for substitutions that conferred known fluco-
nazole resistance mutations36. The Y132F substitution in
ERG11 was identified in all outbreak isolates, confirming
an Indian/Pakistani origin. Lockhart et al.1 also found that
these substitutions were strongly correlated with geo-
graphic clades.
Interpretation of typing results in relation to epidemiology
of the outbreak
C. auris outbreak isolates were grouped into three
phylogenetic clusters (Clades A, B, and C; 18.5%, 63%, and
18.5%, respectively) (Fig. 1b). Clade A comprised five
isolates from 2016 that had over 200 SNPs, distinguishing
it from Clade B. On average, <100 SNPs separated the
isolates in Clades B and C. Clade A was introduced into
the hospital in early 2016 and formed the dominant
outbreak strains towards the end of the outbreak; only 134
SNPs separated those isolates. Phenotypic antifungal
susceptibility varied among Clade A isolates: all expressed
elevated MICs to fluconazole (MIC: 128–256 µg/ml) and
susceptibility to echinocandins (micafungin, caspofungin,
and anidulafungin MIC: 0.06–0.12 µg/ml) and 5-
flucytosine (MIC: 0.06 µg/ml) and two clinical isolates
expressed reduced susceptibility to all azoles (MIC: 4–8
µg/ml posaconazole, 8 µg/ml voriconazole, 2–16 µg/ml
itraconazole). This observation suggests that phenotypic
antifungal susceptibility profiling cannot be reliably used
to group genetically indistinguishable strains from noso-
comial outbreaks.
Three patients with isolates in Clade A were admitted to
the ICU. Two patients acquired C. auris while staying in
the ICU, and another patient acquired C. auris within a
surgical admission unit geographically placed next door to
the high dependency unit in the same month, but this unit
did not overlap with the ICU patients. Transmission of C.
auris between different units within this hospital likely
occurred via the movement of C. auris-positive patients
or contaminated equipment. However, we are currently
unable to establish routes of transmission in more detail
because we did not sequence isolates from all patients
during the outbreak and due to the heterogeneous nature
of the founding population.
Epidemiology of individual patient transmission during the
outbreak
Eight isolates within this study were sequential pairs of
isolates from four separate patients (Table 3); we hypo-
thesized that there may have been nosocomial horizontal
transmission between patients and/or their surrounding
environment, as suggested in previous studies4, 9, 10, 18, for
the following pairs of isolates: 16B22a and 16B22b from
patient A (isolated 12 days apart); 16I27a (MICs were not
carried out for this isolate) and 16B27b from patient B
(isolated 1 day later); 16B24a and 16B24b from patient C
(isolated 5 days apart); and 16B15a and 16B15b from
patient D (isolated 32 days apart).
In patient A, isolate 16B22a (recovered from the axilla)
showed resistance to fluconazole only (Table 2). The
subsequent isolate from this patient, 16B22b (isolated
from a central line tip), exhibited resistance to all azole
drugs (Table 2). Many SNPs (n= 277 SNPs) separated the
two isolates (Fig. 1b) into distinct phylogenetic clusters
(16B22a in Clade C and 16B22b in Clade A), suggesting
independent acquisition of the infection by this patient
within the unit. The two isolates from patient B similarly
differed by many SNPs (n= 127 SNPs) but were both
within Clade B. Given that 16I27a (from a body screen
sample) was isolated 1 day prior to 16B27b (recovered
from a positive blood culture), it is likely that this patient’s
diversity represents an heterogenous C. auris population.
In patient C, 16B24b was isolated from a clinical pacing
wire sampled 5 days after the initial isolation of 16B24a
from a sputum sample. These two isolates differ by 161
SNPs and were both placed in Clade B (Fig. 1b). In patient
D, 16B15b showed raised MICs to all echinocandins and
flucytosine, which were not seen in 16B15a. These two
isolates were separated by 120 SNPs and were phylogen-
etically placed in Clade B (Fig. 1b). Our results suggest
that none of these patients were infected with a single,
clonally propagating C. auris strain; instead, the hospital
(and all of its patients) was seeded with a genetically
heterogenous population.
Three isolates (16B25, 16B20, and 16I29a) clustered
closely together with an average difference of 99 SNPs.
16I29a was recovered from the environment around a C.
auris-positive patient (the isolate was not sequenced) and
was placed in Clade C (Fig. 1b). The patient from which
16B20 was recovered was present in an adjacent side
room at the same time, suggesting a potential transmis-
sion between these patients, with 16I29a forming a new
transmission chain of Clade C (Fig. 1b). 16B25 and 16B20
remained phylogenetically classified as Clade B (Fig. 1b).
However, it remains unclear how the organism may have
been transferred between the two rooms and patients.
The third isolate of this cluster (16B25) was recovered
from a patient present in the same room where 16I29a
recovered. The patient was placed in this room 22 days
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after the previous C. auris-positive patient had left the
room and became positive within 14 days of being in this
isolation room.
Two isolates (16I29a and 16I29b) were isolated from the
bed and trolley of a patient with a confirmed C. auris
infection, who later died. However, MICs for these two
environmental isolates were not carried out at the time of
isolation. The genome sequence of the C. auris isolate
from this patient was also not included in this study. A
total of 161 SNPs differed between 16I29a and 16I29b,
which were phylogenetically placed in Clades C and B,
respectively. 16I29b appeared to be ancestral to a number
of isolates in Clade B (Fig. 1b; 16B18, 16I17, 15B6, 16B16,
16I27a, 16B12, and 16B27b), which were, on average,
separated by 122 SNPs.
Discussion
C. auris is an MDR fungal pathogen with intrinsically
reduced susceptibility to antifungal drugs37 that is capable
of causing invasive infections. Here, we report WGS of C.
auris infections from the largest UK outbreak to date,
which occurred between April 2015 and November 2016
in a London hospital ICU and spread to two other wards.
A gold standard reference genome for the outbreak was
assembled using long MinION-generated reads and Illu-
mina short reads. While the GC nucleotide bias and base
quality in >80% GC regions of the genome were similar in
both Illumina and MinION sequencing, Illumina
sequencing was more consistent across the whole genome
(Figure S1). MinION reads displayed wide variation in
base quality in >85% AT regions, ranging from a quality
Table 3 Clinical isolates of C. auris included in this study
Isolate ID Sequencing technology Isolate date Site Origin
15B5 MinION, Illumina 19/10/2015 Vascath site Patient
15B6 Illumina 22/10/2015 Swan ganz tip Patient
15B10 Illumina 28/12/2015 Groin swab Patient
16B12 Illumina 04/01/2016 Axilla Patient
16B13 Illumina 11/01/2016 Femoral pulse index continuous cardiac output catheter site Patient
16I29b Illumina 18/01/2016 Bed Environment
16I29a Illumina 18/01/2016 Bed window trolley Environment
16B18 Illumina 01/02/2016 Central venous pressure catheter tip in arm Patient
16B15a MinION, Illumina 06/02/2016 Blood culture Patient D
16I17 Illumina 08/02/2016 Screen Patient
16B20 MinION, Illumina 16/02/2016 Blood culture Patient
16B16 Illumina 21/02/2016 Urine catheter Patient
16B21 MinION, Illumina 22/02/2016 Axilla swab Patient
16B22a Illumina 27/02/2016 Axilla swab Patient A
16B24a Illumina 07/03/2016 Sputum Patient C
16B22b Illumina 09/03/2016 Femoral central venous pressure catheter Patient A
16B15b Illumina 09/03/2016 Central venous pressure tip Patient D
16B24b Illumina 12/03/2016 Pacing wire Patient
16B25 MinION, Illumina 13/03/2016 Extracorporeal membrane oxygenation site Patient C
16I27a Illumina 14/03/2016 Screen Patient B
16B26 Illumina 14/03/2016 Extracorporeal membrane oxygenation site Patient
16B27b Illumina 15/03/2016 Blood culture Patient B
16I30 Illumina 21/03/2016 Screen Patient
16I33 Illumina 16/06/2016 Groin Patient
16B31 Illumina 16/10/2016 Central venous pressure line site Patient
16B30 Illumina 17/10/2016 Groin Patient
16I34 Illumina 23/10/2016 Axilla swab Patient
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score of zero to 1.4, whereas Illumina reads ranged
between quality scores of 0.75 and 0.85 for regions >85%
AT. ONT has since released new chemistry that improves
read quality and therefore variant calling, which may
provide a competitive alternative to Illumina sequencing
to further resolve transmission networks in outbreak
settings and routine research.
Rapid generation of a genome assembly using MinION
compliments the mapping of Illumina short reads to call
high-confidence SNPs, which is of great importance in an
outbreak23, 24. Indeed, the use of Illumina data alone
would not have yielded an assembly of similar quality
(Table S1), highlighting the need for long reads, such as
those generated by MinION. SNPs in ERG11 correlated
with known C. albicans hotspots36, conferring resistance
to the frontline drug fluconazole. Currently, no antifungal
clinical breakpoints have been reported for C. auris38. All
C. auris isolates in this study that exhibited high MICs to
fluconazole (≥64 µg/ml) contained the Y132F amino acid
substitution within ERG11, which is known to cause
reduced susceptibility to fluconazole36, 37; seven isolates in
which MIC determination was not carried out or the MIC
was below the ECOFF of 64 µg/ml also contained amino
acid substitutions known to cause reduced susceptibility
to fluconazole. The ECOFFs at the time of publication are
tentative3 and are not breakpoint MICs. Without per-
forming the necessary allele swaps via gene deletion and
observing wild-type phenotypes with lowered MICs to
fluconazole, these ERG11 mutations cannot be confirmed
as the sole mechanism of reduced susceptibility in C.
auris. Thirteen isolates with reduced susceptibility to
fluconazole also displayed elevated MICs for voriconazole
and/or itraconazole. This cross-:“resistance” to multiple
azole drugs has been reported in other studies4, 12, 39, yet
no mechanism has been reported. Expression level
changes of CDR1 have been associated with elevated
itraconazole and fluconazole MICs in C. glabrata40,
whereas MDR1, MRR1, and GRP2 are differentially
expressed in fluconazole and voriconazole resistant C.
albicans isolates41. Differential expression of ERG11,
ERG6, and UPC2 was also associated with posaconazole
resistance in C. albicans41. We did not identify a SNP-
based mechanism responsible for the reduced posacona-
zole resistance in this study. Future studies therefore need
to focus on the molecular biology of C. auris to elucidate
the mechanisms of cross-resistance.
Five isolates displayed reduced susceptibility to
amphotericin B, which although a rare event in Candida
species, has been identified in up to 35% of C. auris iso-
lates, suggesting an intrinsic resistance to this drug1. No
SNPs were associated with this reduced susceptibility,
suggesting that a non-mutation-based mechanism of
resistance is responsible. Thirteen isolates were MDR for
more than one azole drug, and six displayed reduced
susceptibility to two or more classes of antifungal drugs,
posing an important clinical challenge in the treatment of
these C. auris infections. Within this study, we have also
highlighted reduced susceptibility to posaconazole in
addition to reduced susceptibility to echinocandin and
flucytosine in one MDR isolate.
Echinocandin resistance is linked to mutations in the
FKS genes in other Candida species42, and our analysis
identified the S652Y mutation in FKS1 in an
echinocandin-resistant isolate; because the annotation
pipeline in this study predicted an extended first exon,
this mutation is analogous to position 639 in the FKS1
sequence submitted to GenBank, resulting in a S639Y
mutation in HS1. Previous studies have reported S639P
and S639F mutations in C. auris FKS137, 43; this finding
suggests that different mechanisms of echinocandin
resistance are present within the C. auris population,
which is similar to previous observations in ERG11
mutations1. Flucytosine resistance was observed in the
same isolate and was associated with the F211I mutation
in FUR1. Our analysis suggests that systemic echino-
candin and flucytosine treatment can rapidly select for
resistant genotypes across the outbreak timescale. Rapid
MinION sequencing of C. auris isolates holds the promise
of allowing the identification of drug resistance mutations,
thus providing time-sensitive information in a clinical
setting.
Phylogenomic analysis showed weak support for the
monophyletic status of isolates within the hospital, sug-
gesting that multiple introductions of C. auris occurred.
On average, only 240 SNPs separated the UK outbreak
isolates from the Indian/Pakistani clade, clearly showing
that the UK outbreak had an Asian origin. When com-
pared to other sequenced Asian C. auris isolates
(Table S3) in Lockhart et al.1, these SNP numbers suggest
an anomalous amount of diversity within this outbreak.
Future alignments will require clade-specific references
due to the large evolutionary distances between the South
American/African and Indian/Pakistani clades. Although
the mode of introduction into the UK is unknown, tem-
poral analysis of the outbreak isolates placed the most
recent common ancestor as early March 2015, which
correlates closely to the first confirmed infection within
the hospital one month afterwards, suggesting a recent
introduction into the UK.
Only 161 SNPs separated hospital environment isolates
(bed and trolley of a confirmed C. auris-infected patient).
C. auris was also recovered from inanimate surfaces,
suggesting a population of genotypes are capable of
contaminating the hospital environment, causing onward
infection of human hosts1. Given the SNP differences
between isolates recovered from the same patient at dif-
ferent bodily locations (patient A, B, C, and D), the out-
break diversity is either due to multiple introductions,
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which is unlikely as all patients screened negative for C.
auris upon admission, or a genetically heterogenous
population seeded the hospital. Further, given the sub-
stantial number of SNPs separating the two isolates that
were recovered from patient B 24 h apart, it is clear that
genetically disparate isolates can infect the same host at
the same time. The genomic diversity of C. auris within
this outbreak makes mapping local-scale transmission
events difficult as genetic bottlenecks may result in rapid
changes in allele frequencies within local spatiotemporal
scales. Clearly, sequencing multiple isolates of C. auris
from patients alongside those from other UK outbreak
settings is needed to more finely resolve the population
genomic structure of this pathogen to better understand
regional and local-scale transmission dynamics.
This study represents the first use of an ONT MinION
sequencer on a human fungal pathogen; the rapid avail-
ability of long reads demonstrates that this technology is
ideally used in an outbreak setting to provide high-quality
contiguous assemblies. The association of a nsSNP in
FUR1 with flucytosine resistance is both clinically relevant
and novel. Although previous studies have reported FKS1
mutations, the S652Y mutation associated with echino-
candin resistance presented here has not been previously
reported. Further investigation into these mutations is
required to confirm these associations.
Epidemiological analysis suggests that contact tracing
was not sufficient for resolving fine-scale spatiotemporal
processes across the outbreak due to multiple differential
episodic selection events occurring across a genetically
heterogenous C. auris population. Although the genomic
approaches underpinning this study will likely be cor-
nerstones of future research into this increasingly
important pathogen, future research into C. auris should
focus on sequencing many isolates from the same patient
in multiple body sites to correctly establish the nature of
persistence and transmission of C. auris within hospital
environments. By combining molecular epidemiology
with the traditional “shoe leather” epidemiology of contact
tracing and interviewing patients, we will further our
understanding of C. auris to achieve better control of
future outbreaks.
Methods
Hospital and patient information
C. auris isolates were recovered from patients treated at
the Royal Brompton Hospital (London, UK), a specialist
cardiothoracic tertiary hospital. The outbreak was con-
fined to adult patients in the mixed surgical and medical
ICU, high dependency units (HDU) and the surgical
admission ward (on a different floor). Details of the C.
auris outbreak are reported in Schelenz et al.11 Echino-
candin treatment was prescribed in suspected C. auris
infections. If a urinary tract infection was suspected,
combination therapy of amphotericin B and 5-flucytosine
was prescribed. Clinical data were collected as part of an
approved Royal Brompton Hospital Trust service
evaluation.
Fungal isolates
Twenty-seven C. auris isolates were studied, consisting
of 25 clinical isolates from 21 patients and two isolates
collected from the room of a patient known to be colo-
nized with C. auris in the ICU (Table 3). The identifica-
tion of C. auris was conducted by matrix-assisted laser
desorption/ionization time of flight (MALDI-TOF) mass
spectrometry (Bruker Daltonics, Fremont, CA, USA). An
ethanol-formic acid extraction procedure was followed
according to the manufacturer’s protocol for the identi-
fication of C. auris isolates. The spectra were analyzed
using Flex Control 3.1 software (Bruker Daltonics Inc.,
Billerica, MA, USA) and MALDI Biotyper OC version 3.1
(Bruker Daltonics, Bremen, Germany). Scores were
interpreted as >2.0 for species-level identification.
Storage of C. auris isolates
All Candida isolates were stored in 50% glycerol solu-
tion at −70 °C. Isolates were subcultured onto Sabouraud
dextrose agar (SDA; Oxoid Ltd., Basingstoke, UK) and
incubated at 35 °C (±2°C) in ambient air for 18−48 h to
ensure adequate growth when required for further
experimentation.
Antifungal susceptibility testing (AFST)
AFST of 9 systemic antifungal agents (amphotericin B,
flucytosine, fluconazole, itraconazole, voriconazole, posa-
conazole, caspofungin, anidulafungin, and micafungin)
was performed by colorimetric Sensititre YeastOne YST-
10 broth dilution panels (Thermo Fisher Scientific, UK)
according to the manufacturer’s instructions. Quality
control was performed by testing Candida krusei ATCC®
6258 and Candida parapsilosis ATCC® 22019. All MICs
were confirmed in the National Mycology Reference
Laboratory, Public Health England, Bristol, UK, using
broth microdilution according to CLSI method M27-
A344.
gDNA extraction for MinION sequencing
C. auris isolates were grown in 10ml of YPD broth
(Sigma-Aldrich, UK) for 48 h at 37°C with agitation (180
rpm). High-molecular weight genomic DNA was extrac-
ted using the standard MasterPure Yeast DNA purifica-
tion kit (Epicentre Biotechnologies, Cambridge, UK).
Extracted gDNA was quantified using a Qubit 2.0 fluo-
rometer and dsDNA BR (double-stranded DNA, broad
range) assay kit (Life Technologies, Carlsbad, CA, USA).
Quality control of gDNA prior to library preparation was
performed using gDNA ScreenTape assays on the
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TapeStation 2200 system (Agilent, Santa Clara, CA, USA).
Purified gDNAs were stored at 4°C until library
preparation.
High-molecular-weight DNA (1 µg) was fragmented
using a Covaris G-Tube (Covaris, Woburn, USA) at 4200
rpm. Fragmented DNA was end-repaired using the
NEBNext Ultra II (New England Biolabs, Ipswich, USA),
and cleaned using Agencourt AMPure XP beads (Beck-
man Coulter, USA) with a ratio of 1:1 beads to DNA
mixture. End-repaired DNA was then A-tailed using the
NEB Blunt/TA-ligase master mix (New England Biolabs,
Ipswich, USA). The sequence-ready library was purified
using MyOne Streptavidin C1 beads (Thermo Fisher
Scientific, USA) and diluted prior to loading into the
MinION flowcell. A 48-hour sequencing protocol was
initiated using the MinION control software MinKNOW
(v0.51.1.62). Read event data were base-called by the
software Metrichor (v2.39.3). Each library was run on two
flow cells to improve overall coverage.
gDNA extraction for Illumina sequencing
High-molecular weight genomic DNA was extracted
with an optimized MasterPure Yeast DNA purification kit
(Epicentre Biotechnologies, Cambridge, UK) with an
additional bead-beating step. Extracted gDNA was
quantified as mentioned previously. Purified gDNA was
stored at 4 °C until library preparation. All Nextera library
preparation and Illumina HiSeq 2500 sequencing of 2 ×
250 bp paired end reads was carried out by MicrobesNG
(University of Birmingham, UK). Four additional isolates
(16B30, 16B31, 16I33, and 16I34) from a later stage of the
outbreak (from June 2016 to October 2016) were
sequenced using TruSeq Nano library preparation and
Illumina HiSeq 2500 sequencing of 2 × 250 bp paired end
reads at The Centre for Genomic Pathogen Surveillance
(Wellcome Genome Campus, Cambridge, UK).
Library preparation and sequencing
Five clinical isolates (Table 3) representing a 146-day
time frame were chosen for sequencing using the hand-
held MinION sequencer (Oxford Nanopore Technolo-
gies, Oxford, UK) to generate whole genome references
and provide genome annotations to observe the merit of
the sequencing technology.
Twenty-three isolates (Table 3), which include the five
clinical isolates sequenced using MinION, were chosen
for the current gold standard (Illumina sequencing) using
the Nextera library preparation method as part of the
MicrobesNG service (University of Birmingham, UK).
The remaining four isolates were sequenced using TruSeq
library preparation. These isolates represented a 155-day
time frame and included isolates from patients and the
environment around infected patients. Isolates of C. auris
for both MinION and Illumina sequencing were cultured
as described in supplementary methods. All raw reads in
this study have been submitted to the European Nucleo-
tide Archive under project accession PRJEB20230. Details
of genome assembly and annotation are described
in supplementary methods.
Assembly of MinION and Illumina reads
MinION reads were extracted using poRe45. Hybrid
assembly of Illumina and nanopore reads was performed
for each isolate using SPAdes (v3.9.0) with default k-mer
lengths (21, 33, and 55) and 1D scaffolding. An assembly
statistics summary for each hybrid assembly is provided in
Table S1. The hybrid assembly of isolate 16B25 provided
the best statistics, so it was used as a reference for SNP
calling. The genome assembly has been submitted to
NCBI under the project accession PRJNA392455.
Genome annotation
The C. auris genome was annotated using Genemark46,
BLASTx against SwissProt47 and KEGG48, and HMMER
hmmscan49 against PFAM50 and TIGRFAM51. We ran
tRNAscan52 and RNAmmer53 to identify non-protein
coding genes. Gene predictions were checked for a variety
of issues, including overlap with non-coding genes,
overlap with coding genes, and the presence of in-frame
stops. Genes were named according to BLAST and
HMMER evidence in the following order of precedence:
(1) SwissProt, (2) TIGRfam, and (3) KEGG, where BLAST
hits must meet the 70% identity and 70% overlap criteria
to be considered a good hit and for the name to be
applied. Otherwise, genes were named hypothetical pro-
tein. The gene annotations can be found at https://
figshare.com/articles/Candida_auris_gene_annotations/
5203618.
Alignment of Illumina reads and phylogenetic analysis
Raw Illumina reads were quality checked using FastQC
(v0.11.3; Babraham Institute) and aligned to the hybrid
16B25 reference genome using Burrows-Wheeler Aligner
(BWA) v0.7.8 mem54 and converted to sorted BAM for-
mat using SAMtools v1.3.155. Picard v2.6.0 and GATK
v3.656 were used to pre-process the alignments prior to
variant calling. Base recalibration was also performed
using GATK. Variants were called using GATK Haplo-
typeCaller, excluding repetitive regions as identified using
RepeatMasker v4.0.657, and filtered using parameters “DP
< 10||MQ < 40.0||QD < 2.0||FS > 60.0||ABhom < 0.9”.
Next, all variant calls that had a less than a minimum
genotype quality of 50 were removed.
Phylogenies for whole genome SNP data were con-
structed and visualized as described in Rhodes et al.58 The
rate of evolution (represented as the number of sub-
stitutions per day) along the tree topology was estimated
using TempEst v1.5.159 and calibrated with sampling
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times. Root-to-tip regression was calculated, and the root
of the tree was selected to maximize R2.
Benchmarking against CDC bioinformatics pipeline
Our bioinformatics pipeline was also used to call SNPs
from isolates within the Indian/Pakistani clade presented
in Lockhart et al.1 to confirm the genetic diversity
between UK C. auris isolates in the outbreak; the results
are presented in Table S3.
Mutation identification in ERG11, FKS1, and FUR1 genes
Orthologous sequences to C. albicans ERG11 (SC5314)
were extracted from each C. auris genome. Sequences
were evaluated for amino acid substitutions to mutations
within hot spot regions in C. albicans36 as described in
Lockhart et al.1 Predicted FKS1 and FUR1 genes from the
genome annotation were used to identify the presence or
absence of mutations in C. auris isolates.
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